title: Value of fluorodeoxyglucose positron emission tomography before radiotherapy for head and neck cancer: does the standardized uptake value predict treatment outcome?
abstract: OBJECTIVE
  The aim of this study was to determine if the standardized uptake value (SUV) of fluorodeoxyglucose positron emission tomography (FDG-PET) for head and neck cancer can predict the outcome of radiotherapy and if the SUV is correlated with histological grade, mitosis, and apoptosis.
  
  
  METHODS
  The study included 45 head and neck cancer patients who underwent FDG-PET scanning before radiotherapy. The maximum SUV (SUVmax) of their primary lesions were measured. Biopsy was performed in all patients to determine the histological diagnosis. Altogether, 14 biopsy specimens were available for mitotic and apoptotic cell counts.
  
  
  RESULTS
  The mean SUVmax of T3 tumors was significantly higher than that of T1 (P = 0.01) and T2 (P = 0.011) tumors. The mean SUVmax of stage II disease was significantly lower than that of stage III (P = 0.028) and stage IV (P = 0.007) disease. There was a tendency toward a better locoregional control rate and disease-free survival for the lower SUV group using a cutoff value of 5.5. For 41 patients with squamous cell carcinoma or undifferentiated carcinoma, SUVmax did not reflect the histological grade. There was no correlation between the SUVmax and the mitotic/apoptotic status.
  
  
  CONCLUSIONS
  SUVmax may correlate with the T classification and stage, but there was no predictive value for outcome of radiation therapy. Neither histological grading nor mitotic/apoptotic status is correlated with SUVmax.
authors.affiliation: Department of Radiology, Hokkaido University Graduate School of Medicine, Nishi 7-chome Kita 15-Jo, Kita-ku, Sapporo 060-8638, Japan. keishiro@sap-cc.go.jp
authors.forename: Keishiro
authors.initials: K
authors.lastname: Suzuki
authors.forename: Takeshi
authors.initials: T
authors.lastname: Nishioka
authors.forename: Akihiro
authors.initials: A
authors.lastname: Homma
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Tsuchiya
authors.forename: Motoaki
authors.initials: M
authors.lastname: Yasuda
authors.forename: Hidefumi
authors.initials: H
authors.lastname: Aoyama
authors.forename: Rikiya
authors.initials: R
authors.lastname: Onimaru
authors.forename: Nagara
authors.initials: N
authors.lastname: Tamaki
authors.forename: Hiroki
authors.initials: H
authors.lastname: Shirato
mesh_terms: D008949:Adenoma, Pleomorphic / Q000000981:diagnostic imaging* / Q000473:pathology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D017209:Apoptosis; D003528:Carcinoma, Adenoid Cystic / Q000000981:diagnostic imaging* / Q000473:pathology; D002294:Carcinoma, Squamous Cell / Q000000981:diagnostic imaging* / Q000473:pathology; D019788:Fluorodeoxyglucose F18; D006258:Head and Neck Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D008938:Mitosis; D009367:Neoplasm Staging; D010614:Pharynx / Q000000981:diagnostic imaging / Q000473:pathology; D049268:Positron-Emission Tomography / Q000379:methods*; D011237:Predictive Value of Tests; D019275:Radiopharmaceuticals; D055815:Young Adult
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18